Several blood-based screening biomarkers have been used or are currently used in clinical practice, e.g., alpha-fetoprotein for liver cancer, PSA for prostate cancer, CA19-9 for pancreatic cancer, and CA125 for ovarian cancer, among others [131]. This evidence concerns the gene KLK3 and prostate carcinoma.